- Home
- EDTK vs GTBP Comparison
EDTK vs GTBP Comparison
Compare EDTK & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | GTBP |
|---|---|---|
| Founded | 2013 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 12.4M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EDTK | GTBP |
|---|---|---|
| Price | $0.92 | $5.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.4K | ★ 49.2K |
| Earning Date | 08-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.22 |
| 52 Week High | $1.36 | $287.50 |
Technical Indicators
Market Signals| Indicator | EDTK | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 36.75 |
| Support Level | $0.88 | $0.22 |
| Resistance Level | $1.05 | $7.73 |
| Average True Range (ATR) | 0.08 | 0.69 |
| MACD | -0.00 | 0.51 |
| Stochastic Oscillator | 44.11 | 21.16 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.